AKT1 and prostate carcinoma: In prostate cancer cells, Apl-1 treatment increased PARP cleavage and activated caspase-3 expression, and inhibited the expression of anti-apoptotic proteins p-Akt (ser473), p-mTOR (ser2448), XIAP, and Bcl-2 (Figure 3d and Figure S2b).